Intelligence Feed event · Policy · 2026-09-24

    Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease

    Question

    Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease

    Direct answer

    Ionis Pharmaceuticals announced positive data across two partnered Phase III clinical programs. In the FUSION study, antisense candidate ulefnersen achieved its primary endpoint for patients with FUS-associated amyotrophic lateral sclerosis (FUS-ALS), prompting development partner Otsuka to initiate regulatory discussions. Concurrently, the IMAgINATION Phase III trial evaluating sefaxersen in patients with IgA nephropathy (IgAN) demonstrated statistically significant reductions in proteinuria. Both trial readouts validate Ionis' RNA targeting platform in rare neurodegenerative and renal indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/ionis-reports-positive-phase-iii-endpoints-in-als-and-kidney-disease-7c4585

    POLICY
    Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
    Ionis Pharmaceuticals announced positive data across two partnered Phase III clinical programs. In the FUSION study, antisense candidate ulefnersen achieved its primary endpoint for patients with FUS-associated amyotrophic lateral sclerosis (FUS-ALS), prompting development partner Otsuka to initiate regulatory discussions. Concurrently, the IMAgINATION Phase III trial evaluating sefaxersen in patients with IgA nephropathy (IgAN) demonstrated statistically significant reductions in proteinuria. Both trial readouts validate Ionis' RNA targeting platform in rare neurodegenerative and renal indications.
    IONSAZN
    Impact
    75
    SEP 24
    SIG
    85%
    IONSAZN
    Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
    Ionis Pharmaceuticals announced positive data across two partnered Phase III clinical programs. In the FUSION study, antisense candidate ulefnersen achieved its primary endpoint for patients with FUS-associated amyotrophic lateral sclerosis (FUS-ALS), prompting development partner Otsuka to initiate regulatory discussions. Concurrently, the IMAgINATION Phase III trial evaluating sefaxersen in patients with IgA nephropathy (IgAN) demonstrated statistically significant reductions in proteinuria. Both trial readouts validate Ionis' RNA targeting platform in rare neurodegenerative and renal indications.
    → Primary endpoint success in FUS-ALS and IgAN accelerates partner milestone receipts and future royalty cash flow models for IONS.
    Impact
    Ionis Pharmaceuticals announced positive data across two partnered Phase III clinical programs. In the FUSION study, antisense candidate ulefnersen achieved its primary endpoint for patients with FUS-associated amyotrophic lateral sclerosis (FUS-ALS), prompting development partner Otsuka to initiate regulatory discussions. Concurrently, the IMAgINATION Phase III trial evaluating sefaxersen in patients with IgA nephropathy (IgAN) demonstrated statistically significant reductions in proteinuria. Both trial readouts validate Ionis' RNA targeting platform in rare neurodegenerative and renal indications.
    Affected
    IONSAZN
    Transmission
    Primary endpoint success in FUS-ALS and IgAN accelerates partner milestone receipts and future royalty cash flow models for IONS.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSbiotech pipeline derisking and anticipated regulatory milestone paymentsUp1-4wPositive Phase III FUSION and IMAgINATION study outcomes for ulefnersen and sefaxersen.
    AZNrare disease and antisense RNA therapeutic market expansionUp1-3mAstraZeneca maintains strategic RNA-targeted therapeutics collaborations in rare renal and neurological diseases.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSUpagreed43.81 2026-09-24+1.57%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month